Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2;

Read the full 218 word article

User Sign In